Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC vs lapatinib + capecitabine in HER2-positive advanced breast cancer with liver metastases
CTR20180492Phase 3Completed
- Sponsor
- RemeGen
- Start
- May 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin in breast cancer, sponsored by RemeGen. Started May 2018; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20180492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180492.